Updates are available Correction dated 2023-09-11
Click to view Correction: https://doi.org/10.1007/s40261-023-01305-3
-
Authors
Fein, Luis
Lazaretti, Nicolas
Chuken, Yamil López
Benfield, J. Rogelio González Ramírez
Mano, Max S.
Lobaton, Jose
Korbenfeld, Ernesto
Damian, Fernanda
Lu, Dongrui R.
Mori, Ave
Patyna, Shem J.
Franco, Sandra
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02600923 at ClinicalTrials.govDocuments that mention this clinical trial
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
https://doi.org/10.1007/s40261-023-01294-3
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Accepted: 17 July 2023
First Online: 18 August 2023
Change Date: 11 September 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40261-023-01305-3
Declarations
:
: This study was sponsored by Pfizer Inc. The sponsor was involved in study design and data collection.
: LF, NL, FD, SF, and YLC have no conflicts of interest. JRGRB has served as an investigator in sponsored trials for Pfizer, Bristol Myers Squibb, and MSD and as a sponsored speaker for Pfizer, AstraZeneca, and Novartis. MSM has been compensated for lectures and educational support from Pfizer Brazil. JL has served as a speaker and on a scientific advisory board for Roche, MSD, AstraZeneca, Pfizer, and Novartis. EK has received fees from Pfizer for participating in the clinical trial. DRL and SJP are employees of and own stock in Pfizer Inc. AM is an employee of and owns stock in Pfizer S.r.l.
: The protocol was approved by the independent ethics committees or institutional review boards at each of the sites participating in the study (see supplementary material). The study was conducted in compliance with the ethical principles derived from the Declaration of Helsinki.
: All patients provided written informed consent at screening before study procedures were performed.
: Not applicable.
: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See ExternalRef removed for more information.
: Not applicable.
: LF, NL, YLC, JRGRB, MSM, JL, EK, FD, and SF contributed to the collection and assembly of data, and manuscript writing. DRL performed the data analysis and interpretation, and contributed to the manuscript writing. AM and SJP contributed to the concept and design, and the manuscript writing. All authors read and approved the final manuscript, and agree to be accountable for all aspects.
